HK1258166A1 - 重組igg fc多聚體 - Google Patents

重組igg fc多聚體

Info

Publication number
HK1258166A1
HK1258166A1 HK19100521.7A HK19100521A HK1258166A1 HK 1258166 A1 HK1258166 A1 HK 1258166A1 HK 19100521 A HK19100521 A HK 19100521A HK 1258166 A1 HK1258166 A1 HK 1258166A1
Authority
HK
Hong Kong
Prior art keywords
multimers
recombinant igg
igg
recombinant
Prior art date
Application number
HK19100521.7A
Other languages
English (en)
Inventor
Rolf Spirig
Fabian Kaesermann
Adrian Zuercher
Con Panousis
Morelli Adriana Baz
Chao-Guang Chen
Original Assignee
CSL Behring Lengnau AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring Lengnau AG filed Critical CSL Behring Lengnau AG
Publication of HK1258166A1 publication Critical patent/HK1258166A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK19100521.7A 2016-01-27 2019-01-14 重組igg fc多聚體 HK1258166A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16152867 2016-01-27
EP16162166 2016-03-24
EP16195116 2016-10-21
PCT/EP2017/051757 WO2017129737A1 (en) 2016-01-27 2017-01-27 Recombinant igg fc multimers

Publications (1)

Publication Number Publication Date
HK1258166A1 true HK1258166A1 (zh) 2019-11-08

Family

ID=57956274

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19100521.7A HK1258166A1 (zh) 2016-01-27 2019-01-14 重組igg fc多聚體

Country Status (13)

Country Link
US (1) US20190119377A1 (zh)
EP (1) EP3408279A1 (zh)
JP (1) JP2019511458A (zh)
KR (1) KR20180100701A (zh)
CN (1) CN108602857A (zh)
AU (1) AU2017213117A1 (zh)
BR (1) BR112018014668A2 (zh)
CA (1) CA3012037A1 (zh)
HK (1) HK1258166A1 (zh)
MX (1) MX2018008339A (zh)
RU (1) RU2018130525A (zh)
SG (2) SG10201911561SA (zh)
WO (1) WO2017129737A1 (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017379900A1 (en) 2016-12-22 2019-06-13 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE
EP3596118B1 (en) 2017-03-15 2024-08-21 Cue Biopharma, Inc. Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer
CN111556895B (zh) 2017-11-14 2024-09-13 中外制药株式会社 抗-c1s抗体及使用方法
DK3723791T3 (da) 2017-12-14 2024-04-08 CSL Behring Lengnau AG Rekombinante igg-fc-multimere til behandling af neuromyelitis optica
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
MX2021002281A (es) 2018-08-30 2021-05-27 Regeneron Pharma Metodos para caracterizar complejos proteicos.
EP3880248A4 (en) * 2018-11-14 2022-08-10 JN Biosciences, LLC MULTIMERIC HYBRID FC PROTEINS FOR IV IG REPLACEMENT
US11161900B2 (en) 2018-12-13 2021-11-02 Argenx Bvba Antibodies that specifically bind to human complement factor C2b
US20220332847A1 (en) * 2019-09-13 2022-10-20 CSL Behring Lengnau AG RECOMBINANT IgG Fc MULTIMERS FOR THE TREATMENT OF IMMUNE COMPLEX-MEDIATED KIDNEY DISORDERS
WO2021055594A1 (en) * 2019-09-20 2021-03-25 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
JP2021063075A (ja) * 2019-10-16 2021-04-22 中外製薬株式会社 抗体、薬学的組成物、および方法
BR112022010096A2 (pt) 2019-12-06 2022-09-06 CSL Behring Lengnau AG Composições estáveis de multímeros fc
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
CN114894911B (zh) * 2022-03-18 2023-10-24 辽宁成大生物股份有限公司 一种控制牛血清产品质量方法
CN115112879A (zh) * 2022-07-01 2022-09-27 重庆艾生斯生物工程有限公司 一种结合物及其在免疫检测中的应用
CN118027155B (zh) * 2024-04-15 2024-07-16 中国人民解放军军事科学院军事医学研究院 一种tpor结合肽及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6205363B2 (ja) * 2011-09-26 2017-09-27 ジェイエヌ バイオサイエンシーズ エルエルシー ハイブリッド定常領域
SG11201408646VA (en) * 2012-07-06 2015-01-29 Genmab Bv Dimeric protein with triple mutations
RU2015118063A (ru) * 2012-10-17 2016-12-10 Ливерпуль Скул Оф Тропикал Медисин Иммуномодулирующие белки
WO2015132365A1 (en) * 2014-03-05 2015-09-11 Ucb Biopharma Sprl Multimeric fc proteins
UY36021A (es) * 2014-03-05 2015-09-30 Ucb Biopharma Sprl Proteìnas fc multimèricas

Also Published As

Publication number Publication date
SG11201805579SA (en) 2018-08-30
CN108602857A (zh) 2018-09-28
BR112018014668A2 (pt) 2018-12-11
SG10201911561SA (en) 2020-02-27
AU2017213117A1 (en) 2018-07-19
MX2018008339A (es) 2018-09-17
JP2019511458A (ja) 2019-04-25
US20190119377A1 (en) 2019-04-25
CA3012037A1 (en) 2017-08-03
RU2018130525A3 (zh) 2020-05-29
RU2018130525A (ru) 2020-02-27
WO2017129737A1 (en) 2017-08-03
EP3408279A1 (en) 2018-12-05
KR20180100701A (ko) 2018-09-11

Similar Documents

Publication Publication Date Title
HK1258166A1 (zh) 重組igg fc多聚體
IL278014A (en) Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use
ZA201701810B (en) Sirp-alpha immunoglobulin fusion proteins
HK1246321A1 (zh) 包含glp和免疫球蛋白雜合fc的融合多肽及其用途
IL247096A0 (en) proteins fc multimers
EP3221456A4 (en) Genome-modified recombinant adeno-associated virus vectors
IL247246A0 (en) proteins fc multimers
GB201509413D0 (en) Fusion protein
EP3188758C0 (en) SIRP-ALPHA ANTIBODY FUSION PROTEINS
HK1232136A1 (zh) 融合蛋白
IL290258A (en) Transgenic Isfahan Viral Vector
EP3199179A4 (en) Recombinant fusion protein formulation
HK1258125A1 (zh) 胰島素免疫球蛋白融合蛋白
EP3199555A4 (en) Recombinant fusion protein formulation
EP3375873A4 (en) POLYPEPTIDE BINDING TO IMMUNOBLOBULINS
GB201504691D0 (en) Fusion protein
HK1257937A1 (zh) 融合蛋白
PL3164492T3 (pl) Układy ekspresji polipeptydu
HK1253854A1 (zh) 抗微生物融合肽
SG11201606501PA (en) Nanobody-fluorescent protein fusion
GB201602850D0 (en) Fusion proteins
SG11202105365RA (en) Modified fc region
GB201617799D0 (en) Fusion polypeptide
GB201503789D0 (en) Fusion polypeptide
TH1501006601A (th) สูตรทางเลือกสำหรับ TNFR:Fc ฟิวชันเพปไทด์